ClinicalTrials.gg
RecruitingNCT06596434Updated Mar 5, 2026

4-Aminopyridine to Treat Skin Burns

A Phase 2 interventional study of Drug: 4-Aminopyridine and Placebo in Burns, Second Degree Burn and Wounds and Injuries, sponsored by John Elfar. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by John Elfar · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 336 studies in Burns with a site in United States — 40 open to participants now, 51 under way, 5 of them phase 3. Burns · United States.

Planned enrollment
19th of 272
200 · median 26
Started
2026
with 14 others
Phase 2
32 of 336
3 open now
Primary completion
2028-06
later than 40 of 50 live
Registered
308th of 336
by date

Among the 336 studies in Burns with a site in United States, this one is the 19th largest by planned enrollment of the 272 interventional ones that give a count, is one of 15 that started in 2026, is one of 32 in phase 2, reaches primary completion later than 40 of the 50 other live ones, and was the 308th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Burns with a site in United States, or all of them as a file.
02

Study summary

Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of 4-AP, a promising new agent with an excellent safety profile, on wound and burn healing. The investigational treatment will be used to test the hypothesis that 4-AP accelerates burn healing in traumatically burned patients.

Read the detailed description

Burn treatment has not appreciably changed in decades. Most treatments focus on infection prevention and control, as well as fluid management. This is because burns are universally infected with bacteria allowed to infiltrate deeper tissues by the absence of a skin barrier. If bacteria can now get into these tissues, the problem is only made worse by the large amount of hydration that now can get out into the environment from the open wound. Desiccation sets in with deeper tissues losing fluids. This renders tissue significantly more susceptible to further infection, as dry tissues are less perfused and less capable of fighting infectious insults. Desiccation also robs burned patients of fluids vital to sustain cardiopulmonary function. Without skin, patients essentially lose fluids and cannot perfuse even the most vital organs with time.

Research in the field focuses on preventing complications and temporizing these two factors. No regenerative treatments are currently offered to accelerate wound healing, and few investigative treatments are ready for translation to human trials. Most of the pipelines for future treatment involve long development timelines and still focus chiefly on infection control instead of driving tissue to regenerate and heal faster. A significant gap is the need for a regenerative burn treatment that can be trialed while still allowing the use of current protocols. An adjuvant regenerative burn treatment is needed.

The purpose of this study is to evaluate the role of local 4-aminopyridine (4-AP) on the treatment of burn wounds to accelerate healing.

03

Conditions studied

  • Burns
  • Second Degree Burn
  • Wounds and Injuries

Keywords

  • 4-aminopyridine
  • 4-AP
  • Burns
  • Second degree burn
  • Wounds
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Injured (burned) adults with a maximum severity of second-degree burns.
  • Burns involving at least 6cm2 of skin area
  • Acute burns within 7 days of injury
  • Cognitive ability to evaluate burn healing, report sensory and motor deficit during examination.
  • Adults aged 18-80
  • Ability to give written .
  • Capable of safely coming in for follow up visits on all scheduled appointments.

Exclusion criteria

Exclusion Criteria:

  • History of multiple sclerosis, stroke or any other diagnosed neurological disorder
  • History of to AMPYRA® or 4-aminopyridine
  • Current use of aminopyridine medications, including other compounded 4-AP
  • Suspected renal impairment based on the Choyke questionnaire.
  • History of difficult compliance with timely follow up
  • Patients outside the age range
  • Unable to provide .
  • Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).
  • Patients with a concomitant traumatic brain injury.
  • Patients unable to communicate.
  • Patients unwilling to complete the study requirements.
  • Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.
  • Pregnancy, breastfeeding or incarcerated individuals.
  • Non-English speaking
  • Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Group A: 4-aminopyridine

    Dalfampridine (generic) 10 mg capsule PO every 12 hours

    Drug: Drug: 4-Aminopyridine

  • Placebo comparator
    Group B: Placebo

    Placebo - 1 capsule PO every 12 hours

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Healing rate

    Each subject will undergo detailed fiducial-marking augmented macroscopic imaging to determine baseline burn area measurement. These measurements will be repeated at each follow up study visit to assess healing rate.

    Time frame: 12 months

Secondary outcomes

  1. Skin-graft rate

    Skin-graft rate (failure of healing)

    Time frame: 12 months

  2. Scar formation

    Scar formation will be measured by the Patient and Observer Scar Assessment Scale (POSAS). Each item of the POSAS is rated on a 10-point score with total scores ranging from 6 to 60 with higher scores indicating increase severity of symptoms. These measurements will be repeated at each follow up study visit.

    Time frame: 12 months

  3. Scar sensitivity

    Scar sensitivity will be measured by the Patient and Observer Scar Assessment Scale (POSAS). Each item of the POSAS is rated on a 10-point score with total scores ranging from 6 to 60 with higher scores indicating increase severity of symptoms. These measurements will be repeated at each follow up study visit to assess healing rate.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2028, 29 months after the start.

Of 17 phase 2 interventional studies under Burns, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2024
First posted
Sep 19, 2024
StartActual
Jan 1, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Sep 2028
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06596434
Lead sponsor
John Elfar
Responsible party
John Elfar (Tenured Professor, Chairman, Department of Orthopaedic Surgery, University of Arizona) — Sponsor-investigator
First posted
Sep 19, 2024
Start date
Jan 1, 2026
Primary completion
Jun 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Mar 5, 2026

Study contacts

Carly J Deal, MPH
Contact
carlyjdeal@arizona.edu
520-626-1588
Veronica Rangel, BS
Contact
vrangel@arizona.edu
5206264024
John Elfar, MD
principal investigator · University of Arizona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4-Aminopyridine

Start the discussion